Skip to main content
. 2019 Dec 6;15:539–550. doi: 10.2147/VHRM.S226009

Table 2.

LVMI, LV Geometric Patterns, Hemodynamics, and Biochemical Profile for the Two Study Groups

Allopurinol Users
N=96
Control Subjects
N=96
P-Value
LVM (g) 161.50 (128.25, 207.00) 140.50 (117.75, 189.50) 0.022
LVMI (g/m2) 81.50 (68.00, 106.75) 79.00 (66.00, 97.75) 0.340
LVMI (g/h2.7) 44.58 (35.53, 54.16) 41.20 (31.07, 49.66) 0.046
RWT 0.345 (0.270, 0.428) 0.340 (0.263, 0.420) 0.849
LV geometric patterns 0.345
Normal geometry (NL) 53 (55.2%) 63 (65.6%)
Concentric remodeling (CR) 21 (21.9%) 17 (17.7%)
Eccentric hypertrophy (EH) 16 (16.7%) 9 (9.4%)
Concentric hypertrophy (CH) 6 (6.2%) 7 (7.3%)
Ejection fraction (%) 0.859
Normal ≥50 50 (52.1%) 54 (56.3%)
Mild dysfunction 40–49 17 (17.7%) 18 (18.7%)
Moderate dysfunction 30–39 12 (12.5%) 11 (11.5%)
Severe dysfunction ˂30 17 (17.7%) 13 (13.5%)
SBP (mmHg) 126.91 ± 19.26 129.23 ± 22.68 0.445
DBP (mmHg) 71.06 ± 12.81 69.74 ± 11.95 0.460
HR (beat/min) 70.00 (63.00, 83.00) 71.00 (62.00, 82.00) 0.895
Biochemistry
HbA1C (%)a 7.00 (6.13, 7.70) 7.65 (6.48, 9.22) 0.004
eGFR (mL/min/1.73 m2)b 33.50 (20.75, 49.25) 60.00 (38.25, 60.00) 0.000
Serum creatinine (mg/dL)b 1.89 (1.21, 2.81) 1.13 (0.90, 1.63) 0.000
Total cholesterol (mg/dL) 131.50 (109.70, 172.20) 131.30 (111.39, 158.31) 0.864
LDL-cholesterol (mg/dL) 77.30 (58.00, 102.50) 77.34 (54.14, 98.42) 0.651
HDL-cholesterol (mg/dL) 35.58 (30.94, 42.92) 36.74 (28.52, 44.37) 0.871
Triglycerides (mg/dL) 130.15 (90.49, 176.33) 123.89 (89.82, 166.15) 0.503

Notes: Data calculated based on the following number of patients; a(84 allopurinol: 82 control), b(94 allopurinol: 96 control).

Abbreviations: g, gram; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVM, left ventricular mass; LVMI; left ventricular mass index; RWT, relative wall thickness; LV, left ventricle.